High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention

2002 ◽  
Vol 105 (5) ◽  
pp. 385-390 ◽  
Author(s):  
Jurriën M ten Berg ◽  
Wim B.M Gerritsen ◽  
Fred J.L.M Haas ◽  
Hans C Kelder ◽  
Freek W.A Verheugt ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Platelet Activation ◽  
Low Dose ◽  
Coronary Intervention ◽  
High Dose ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Percutaneous Coronary ◽  
Before And After ◽  
High Dose Aspirin

scholarly journals LOW-DOSE VERSUS HIGH-DOSE ASPIRIN AFTER PERCUTANEOUS CORONARY INTERVENTION

2011 ◽  
Vol 57 (14) ◽  
pp. E1911 ◽  
Author(s):  
Kishore J. Harjai ◽  
Chetan Shenoy ◽  
Pam Orshaw ◽  
Samer Usmani ◽  
Maninder Singh ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Low Dose ◽  
Coronary Intervention ◽  
High Dose ◽  
Dose Aspirin ◽  
Percutaneous Coronary ◽  
High Dose Aspirin

scholarly journals Safety and efficacy of high-dose versus low-dose aspirin in individuals with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized clinical trial

2019 ◽  
Vol 6 (1) ◽  
pp. e05-e05
Author(s):  
Abdolhossien Emami Sigaroudi ◽  
Arsalan Salari ◽  
Mohadeseh Poursadeghi ◽  
Fatemeh Moaddab ◽  
Seyedeh Fatemeh Mirrazeghi ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Percutaneous Coronary Intervention ◽  
Randomized Trial ◽  
Low Dose ◽  
Coronary Intervention ◽  
Hazard Ratio ◽  
High Dose ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Percutaneous Coronary

Introduction: Aspirin is the most frequently used antiplatelet therapy after percutaneous coronary intervention (PCI). Yet, the optimal daily dose of aspirin is unanswered. Objectives: We aimed to compare the effect of high-dose versus low-dose aspirin in a randomized trial of patients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI. Patients and Methods: In a double-blind randomized trial, 175 patients with STEMI were randomly assigned to high-dose or low-dose aspirin. The primary efficacy outcome was major adverse cardiovascular events (MACE) as a composite endpoint of death, myocardial infarction, stroke and revascularization procedures. The primary safety endpoint was major bleeding. Results: Totally 90 and 85 patients were assigned to high-dose and low-dose aspirin, respectively. The incidence rate of MACE was 13.1 and 10.1 per 100 person year in high-dose and low dose aspirin, respectively. There was no significant difference between high-dose and low-dose aspirin in terms of efficacy (Adjusted hazard ratio: 0.85, 95% CI=0.29-2.45) and safety outcome (Adjusted hazard ratio: 1.65, 95% CI=0.41-6.69). Conclusion: Efficacy and safety outcomes were not significantly different between high-dose and low-dose aspirin.

scholarly journals High dose versus low dose Aspirin after Percutaneous Coronary Intervention in Coronary Artery Disease

2019 ◽  
Vol 16 (2) ◽  
pp. 59-62 ◽  
Author(s):  
Rajib Rajbhandari ◽  
Rikesh Tamrakar ◽  
Yuba Raj Limbu ◽  
Satish Singh ◽  
Sanjay Singh KC
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Low Dose ◽  
Coronary Intervention ◽  
High Dose ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Percutaneous Coronary ◽  
Artery Disease ◽  
Aspirin Group

Background and Aims: Patients with Coronary artery disease who undergo percutaneous coronary intervention (PCI) are prescribed with maintenance aspirin dose that vary between 75 mg to 300 mg daily. The objective of this study is to evaluate the effects of high dose versus low dose aspirin doses prescribed on hospital discharge in PCI. Methods: All the patients who had undergone PCI at our hospital from 2017 February to October 2017 were enrolled in the study. They were divided into two groups receiving low dose (<200mg) aspirin and high dose (>200mg) aspirin. Patients were interviewed on phone after completion of one year for the possible complications and new ischemic events during the follow up period. Results: Among 150 patients selected 101 fulfilled the criteria and sixty patients (59.4%) were discharged on low-dose aspirin 75-150mg and 41 patients (40.6%) were discharged on high-dose aspirin of 300mg. The mean age in low aspirin group was 59.8±13.19 years and 49.4±10.7 years in high aspirin group. Although high aspirin dose patients did not complain of epigastric pain more often, upper GI bleeding was significantly higher in high aspirin group 7.5% vs 11.1% (p<0.05). One patient in high aspirin group had hemorrhagic stroke while low aspirin group had none. One patient in high aspirin had sudden cardiac death at home. Clinically, there was no significant difference in new ischemic events during follow up period. Conclusion: In patients with coronary artery disease undergoing PCI, discharge on high-dose rather than low-dose aspirin may increase the rate of bleeding without providing additional ischemic benefit.

Sign in / Sign up

Export Citation Format

Share Document